Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer — Stella

Home/Pancreatic Ductal Adenocarcinoma (PDAC)/Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

View on ClinicalTrials.gov

Recruiting

Back to Pancreatic Ductal Adenocarcinoma (PDAC) trials

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Key details

Phase

Safety & dosing

Sponsor

UNC Lineberger Comprehensive Cancer Center

Enrollment target

~45 participants

Started

June 2019

Primary completion

July 2027

Age range

18 Years – 99 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.